Drug Interaction Report
3 potential interactions and/or warnings found for the following 2 drugs:
- interferon alfa-2b / ribavirin
- ropinirole
Interactions between your drugs
interferon alfa-2b rOPINIRole
Applies to: interferon alfa-2b / ribavirin, ropinirole
MONITOR: Coadministration with drugs that are inhibitors of CYP450 1A2 may increase the plasma concentrations of ropinirole, which is metabolized by the isoenzyme. Ciprofloxacin (500 mg twice a day), a known inhibitor of CYP450 1A2, has been reported to increase the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of ropinirole (2 mg three times a day) by an average of 60% and 84%, respectively, in 12 study subjects. The possibility of prolonged and/or increased pharmacologic effects of ropinirole should be considered.
MANAGEMENT: Pharmacologic response to ropinirole should be monitored more closely whenever a CYP450 1A2 inhibitor is added to or withdrawn from therapy, and the ropinirole dosage adjusted as necessary. Patients should be advised to contact their physician if they experience excessive adverse effects of ropinirole such as agitation, hallucinations, orthostasis, sedation, confusion, or increased dyskinesia, flushing, dry mouth, sweating, and heart rate.
References (2)
- (2001) "Product Information. Noroxin (norfloxacin)." Merck & Co., Inc
- (2001) "Product Information. Requip (ropinirole)." SmithKline Beecham
Drug and food interactions
ribavirin food
Applies to: interferon alfa-2b / ribavirin
ADJUST DOSING INTERVAL: Food enhances the oral absorption and bioavailability of ribavirin. Administration of a single oral dose of ribavirin following a high-fat meal delayed absorption (Tmax was doubled) but increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by up to 70% compared to administration in the fasting state.
MANAGEMENT: To ensure maximal oral absorption, ribavirin should be administered with or immediately after a meal.
References (2)
- (2003) "Product Information. Copegus (ribavirin)." Roche Laboratories
- (2004) "Product Information. Rebetol (ribavirin)." Schering-Plough Corporation
rOPINIRole food
Applies to: ropinirole
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References (4)
- Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
- Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
- (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
- (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Epclusa
Epclusa treats chronic hepatitis C in adults and children 3+. This once-daily antiviral combines ...
Mavyret
Mavyret (glecaprevir/pibrentasvir) is an oral combination medicine containing fixed doses of two ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Harvoni
Harvoni is used to treat hepatitis C virus (HCV) infections in adults and children aged 3 years and ...
Sovaldi
Sovaldi (sofosbuvir) is used to treat chronic hepatitis C virus (HCV) infection. Includes Sovaldi ...
Vosevi
Vosevi (sofosbuvir,velpatasvir and voxilaprevir) is used to treat chronic hepatitis C. Includes ...
Pegasys
Pegasys is used to treat chronic hepatitis B or C. Learn about side effects, interactions and ...
Zepatier
Zepatier (elbasvir and grazoprevir) is used to treat chronic hepatitis C. Includes Zepatier side ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.